Brief: Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101
07/03/2024 12:03
March 7 (Reuters) - Solid Biosciences Inc SLDB.O :
* SOLID BIOSCIENCES ANNOUNCES LICENSING AGREEMENT WITH
ARMATUS BIO
FOR THE USE OF AAV-SLB101, A PROPRIETARY, MUSCLE-TARGETED
CAPSID, IN THE DEVELOPMENT OF AN RNAI THERAPY TO TREAT FSHD
Source text for Eikon: ID:nGNXbftCwc
Further company coverage: SLDB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Solid Biosciences
See all newsSolid Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Solid Biosciences Inc expected to post a loss of 48 cents a share - Earnings Preview
Solid Biosciences Q2 net loss widens on higher R&D costs
Marketing Agreement To Advance Gene Therapy Delivery And Analytics
Solid Biosciences Q1 net loss widens on higher R&D costs